| Autor: |
Beran, David, Abidha, Carol, Adler, Amanda, de Beaufort, Carine, Lepeska, Molly, Levitt, Naomi, Pfiester, Elizabeth, Zafra Tanaka, Jessica Hanae, Gale, Edwin Am |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
The Lancet Diabetes & Endocrinology. 11:78-80 |
| ISSN: |
2213-8587 |
| DOI: |
10.1016/s2213-8587(22)00384-9 |
| Popis: |
The US Food and Drug Administration's (FDA) approval of teplizumab to delay the onset of type 1 diabetes could be seen as symbolic, because it came a century after the first use of insulin. Teplizumab, an anti-CD3 monoclonal antibody, is now approved in the USA for people at high risk of type 1 diabetes. This approval is a highly welcome development for this population and all those involved in the care and wellbeing of people with type 1 diabetes. However, in our opinion, the approval of teplizumab should be interpreted with caution. A global health perspective must consider evidence, cost, patient preferences, and equity... |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
